Articles

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA
Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA
Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx, NY, USA
Lindsley F. Kimball Research Institute, New York Blood Center, NY, USA
Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Division of Hematology and Oncology, Weill Cornell Medicine /New York Presbyterian Hospital, NY, USA
Division of Hematology and Oncology, Weill Cornell Medicine /New York Presbyterian Hospital, NY, USA
Lindsley F. Kimball Research Institute, New York Blood Center, NY, USA
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lindsley F. Kimball Research Institute, New York Blood Center, NY, USA
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx, NY, USA;Lindsley F. Kimball Research Institute, New York Blood Center, NY, USA
Vol. 103 No. 5 (2018): May, 2018 https://doi.org/10.3324/haematol.2017.187047